FDA warned Ozempen.com it sells unapproved, misbranded semaglutide pens to U.S. consumers online.
What happened
FDA reviewed www.ozempen.com and found it offering “4mg Semaglutide Pen” and “8mg Semaglutide Pen” for sale to U.S. consumers. FDA said there are no approved applications for those products and that their labeling lacks adequate directions for use. The letter says the site claims the products have the same active ingredient as Ozempic, Rybelsus and Wegovy but are more budget friendly.
What FDA found
The website offers semaglutide pens that are new drugs without FDA-approved applications.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]The pens are prescription drugs, but their labeling does not give adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Offering the products for sale causes misbranded drugs to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells Ozempen.com to stop offering any unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 working days with steps taken and documentation to prevent recurrence.
Who should pay attention
- consumers buying semaglutide online
- websites selling imported or unapproved semaglutide
- platforms hosting online pharmacy listings
This is a summary. Read the original letter on fda.gov.